Vaxcyte, Inc., based in San Carlos, CA, is committed to eradicating bacterial infections like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella to safeguard every newborn and vulnerable adult worldwide.
The company is at the forefront of innovation in vaccine development, particularly in addressing the persistent threat posed by Streptococcus pneumoniae bacteria, which continues to pose a significant health risk globally, especially for young children and the elderly.
Vaxcyte leverages cutting-edge technology and unconventional approaches to create high-fidelity, broad-spectrum vaccines that can effectively combat bacteria's defenses while maintaining strong immunogenicity. Their pipeline includes potentially groundbreaking pneumococcal conjugate vaccines like VAX-31 and VAX-24, with ongoing research targeting other bacterial infections as well.
Generated from the website content
